Compare MINISO Group Holding Ltd (MNSO) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Natera Inc. Common Stock — how do they compare? MINISO Group Holding Ltd trades at $10.34 (market cap $2.89B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 19.7× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 6.71% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MINISO Group Holding Ltd for 25 Days and Natera Inc. Common Stock for 0 Days on average.
| MNSO | NTRA | |
|---|---|---|
Market Cap | $2.89B | $57.03B |
Volume | 1,658,211 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.75 | $425.64 |
52-Week Low | $8.60 | $179.42 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $3.76B | $56.18B |
Dividend Yield | 6.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $9.92, up 1.95% with a bullish technical signal despite mixed earnings history. The company shows solid fundamentals with $21.44B revenue, 5.35% net margin, and attractive valuation ratios including P/E of 16.11 and P/S of 0.86. Recent CFO share purchases and analyst optimism (60% buy rating) support positive sentiment, though earnings misses in three of the last four quarters highlight execution risks amid competitive retail pressures.
The outlook remains cautiously optimistic given MNSO's valuation appeal and growth potential, but investors should monitor earnings consistency and overseas margin pressures. Key opportunities include domestic expansion and operational optimization, while risks involve volatile quarterly performance and intense retail competition.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
